^
Association details:
| Biomarker: | KIT L576P |
|---|---|
| Cancer: | Melanoma |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Activity of Dasatinib Against L576P KIT Mutant Melanoma: Molecular, Cellular and Clinical Correlates
Excerpt:
In summary, we have identified the first melanoma cell line that has a naturally occurring L576P KIT mutation, the most common KIT mutation observed in melanoma. Our in vitro and clinical data demonstrate that melanoma cells with this mutation are sensitive to dasatinib, but they are relatively resistant to imatinib.
DOI:
10.1158/1535-7163.MCT-09-0459
